DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the LAURUS LABS LIMITED (LAURUSLABS) share price today?

LAURUS LABS LIMITED (LAURUSLABS) is trading at ₹1,529.8 on the NSE, down 1.78% on the day. Source: DocStoX.

What is the PE ratio of LAURUS LABS LIMITED?

LAURUS LABS LIMITED has a price-to-earnings (PE) ratio of 92.9 in the Healthcare sector.

What is the market capitalisation of LAURUS LABS LIMITED?

LAURUS LABS LIMITED has a market capitalisation of approximately ₹82,511 crore.

LAURUS LABS LIMITED

F&O

LAURUSLABS·NSE·Healthcare

₹1,529.80▼ -27.80 (-1.78%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 200NIFTY 500NIFTY MIDCAP 150

Day₹1520.40

₹1561.00

52W₹810

₹157994%

Open

₹1560.40

High

₹1561.00

Low

₹1520.40

Prev Close

₹1557.60

Volume

10.11L

VWAP

₹1532.71

Snapshot

Key fundamentals

Market Cap

₹82,511 Cr

P/E Ratio

92.94Expensive

P/B Ratio

15.32

EPS

₹16.46

Book Value

₹98.20

ROE

18.30%Strong

ROCE

18.00%Decent

Dividend Yield

0.13%

Debt / Equity

0.48Moderate

Face Value

₹2.00

52W High

₹1579.10

52W Low

₹810.05

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹139

▼ 90.9%downside

Trading at ₹1,530 — 91% above our estimate

BearFair valueBull

₹118₹139₹191

/100

Business quality — Watch the fundamentals

Growth 16Profitability 64Efficiency 25Valuation 38

Plain English

Our view

A steady, established business
Low debt relative to equity
Expensive — trades at 93× earnings

Strengths

Low debt relative to equity

Risks

Expensive — trades at 93× earnings
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

18% ROE fading to 13% over ~10 yrs, on ₹98 book

₹125

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹191

Analyst target

No analyst coverage

—

Blended fair value₹139

What the numbers say

Investment thesis

Bull case

Low debt relative to equity

Bear case

Expensive — trades at 93× earnings
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

92.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

18.3%Strong

Above 15% is considered healthy for Indian equities

ROCE

18.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.48Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹82,511 Cr

P/B

15.32

EPS

₹16.46

Div Yield

0.13%

What changed

Recent changes

Foreign investors-0.7% stake last quarter
Domestic institutions+1.5% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 92.9×

Growth

Slow

+4% rev CAGR

Profitability

Excellent

18.3% ROE

Financial health

Comfortable

D/E 0.48

Momentum

N/A

No technicals

Today

Trading activity

Delivery %52.2%

Turnover₹15495.92L Cr

Trades37,105

VWAP₹1532.71

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+4.1%

+7.2%

10Y

+14.4%

Profit

+3.9%

-2.0%

10Y

+20.8%

EPS

+3.9%

-2.1%

10Y

-0.3%

Profile

Pros

Company has been maintaining a healthy dividend payout of 19.0%

Watch-outs

Cons

Stock is trading at 15.7 times its book value
The company has delivered a poor sales growth of 7.19% over past five years.
Company has a low return on equity of 10.1% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.70 pts; domestic institutions added 1.54 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

27%

Promoter

Promoters

27.5%0.00

Public

32.7%-0.84

FII / FPI

25.8%-0.70

DII

14.0%+1.54

Total shareholders

2,92,281+11,525 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter27.49%

FII25.82%

DII13.96%

Public32.73%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O